(MRK) and Daiichi Sankyo on Thursday said that the companies have withdrawn their application to the U.S. Food and Drug ...

(RTTNews) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi ... said Ken Takeshita, Global Head ...

Daiichi Sankyo's head of global R&D, Ken Takeshita, said that EGFR-mutated NSCLC is known to be difficult to treat in the second-line metastatic setting, but added that the company is "conducting ...

Daiichi Sankyo research and development global head Ken Takeshita said: “While we are disappointed with the OS results of HERTHENA-Lung02, we are conducting further biomarker analyses to better ...

“Our goal is to push the boundaries of science to change the way cancer is treated,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “These data reinforce the breadth and depth of ...

When Merck & Co. and Daiichi Sankyo last year received an FDA complete ... multiple clinical trials across 15 types of cancer," Ken Takeshita, M.D., Daiichi's global head of R&D, said in a statement.

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

"Expanding our oncology pipeline with a DLL3 T-cell engager further supports Daiichi Sankyo’s strategy to create new standards of care for patients with cancer worldwide," said Ken Takeshita ...

Daiichi Sankyo has won Japanese approval for Ezharmia ... overcome the weakness of EZH2 blocking alone, global R&D chief Ken Takeshita, M.D., explained during an investor event in December.

Progress in Lung Cancer Across Daiichi Sankyo’s DXd ADC Portfolio Updated DATROWAY® (datopotamab deruxtecan) combination data across three early-phase trials will be highlighted in patients ...

1 “Expanding our oncology pipeline with a DLL3 T-cell engager further supports Daiichi Sankyo’s strategy to create new standards of care for patients with cancer worldwide,” said Ken Takeshita, MD, ...

Today we have Okuzawa, the Representative Director, President and COO; Ogawa of Executive Officer and CFO; and Takeshita ... results presentation for Daiichi Sankyo. We have announced FY 2023 ...